There is one clinical trial.
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in
healthy adults above 18 years of age. This clinical trial is designed to evaluate the
immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of
SARS-CoV-2.
Primary Outcomes
Measure: Occurrence of adverse reactions Time: 0-14 days post vaccination
Measure: Anti SARS-CoV-2 S IgG antibody response(ELISA) Time: 28 days post vaccination
Measure: Neutralizing antibody response to SARS-CoV-2 Time: 28 days post vaccination
Secondary Outcomes
Measure: Occurrence of adverse events Time: 0-28 days post vaccination
Measure: Occurrence of serious adverse reaction Time: 0-6 months post vaccination
Measure: Anti SARS-CoV-2 S IgG antibody response(ELISA) Time: 0, 14 days and 6 months post vaccination
Measure: Neutralizing antibody response to SARS-CoV-2 Time: 0 and 6 months post vaccination
Measure: Neutralizing antibody response to Ad5-vector Time: 0, 28 days and 6 months post vaccination
Measure: IFN-γ ELISpot responses to SARS-CoV-2 spike protein Time: 0 and 28 days post vaccination